Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

CNBC reports Pfizer beat quarterly estimates and raised the lower end of its full-year revenue guidance, driven by strong performance in its non-COVID product lineup. The company is now forecasting full-year COVID-related revenue of four billion dollars, down from approximately five billion dollars previously.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton